An opioid made in the brain is crucial for remembering others
It would be inconvenient if we couldn’t remember the people we have or haven’t met before. Social recognition, the ability to differentiate familiar or novel individuals of the same species is part of a larger process of social memory that allows groups within a species to build and maintain stable networks or relationships, like what we know as friend groups or communities.

The hippocampus, known for its role in memory, is divided into subregions that contribute to different memory processes, and one called CA2 is particularly important for social memory. Scientists have found one particular neurochemical to be important in social recognition. Enkephalin, a neuropeptide that interacts with opioid receptors, is needed in CA2 to recognize new people.
Enkephalins belong to a class of opioids produced by the brain which are often associated with stress response and pain relief. The researchers found that in CA2, these compounds are released by specific type of neuron, boosting information transfer to the CA2, thus enabling our brains to form social memories.
Scientists studied the effects of enkephalin through a social memory test in mice. They introduced one mouse to a space with two others, and the subject mouse was allowed to interact with each mouse for fiver minutes. The subject mouse was removed, then returned half an hour later, this time with one of the mice from the last entry and one mouse it had not met before. The typical response for mice in this case is to pay attention to the new mouse for longer. The scientists observed that, while mice with regular enkephalin levels sniffed out the new mouse for a longer amount of time, mice without enkephalin spent the same amount of time between both mice, as if they had not previously encountered one of them.
A better understanding of social memory can help demystify related diseases. Schizophrenia, a condition in which social memory is impaired, is treated with drugs affecting opioid receptors, for example. The results of this study shed light on how these treatments work.
This story originally appeared on Massive Science, an editorial partner site that publishes science stories by scientists. Subscribe to their newsletter to get even more science sent straight to you.
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Mass spec method captures proteins in native membranes
Yale scientists developed a mass spec protocol that keeps proteins in their native environment, detects intact protein complexes and tracks drug binding, offering a clearer view of membrane biology.

Laser-assisted cryoEM method preserves protein structure
University of Wisconsin–Madison researchers devised a method that prevents protein compaction during cryoEM prep, restoring natural structure for mass spec studies. The approach could expand high-resolution imaging to more complex protein systems.

Method sharpens proteome-wide view of structural changes
Researchers developed a method that improves limited proteolysis coupled with mass spectrometry, separating true changes from abundance or splicing effects.

Discoveries made possible by DNA
The discovery of DNA’s double helix revealed how genetic information is stored, copied and expressed. Revisit that breakthrough and traces how it laid the foundation for modern molecular biology, genomics and biotechnology.

Unraveling the language of histones
Philip Cole presented his research on how posttranslational modifications to histones are involved in gene expression and how these modifications could be therapeutically targeted to treat diseases like cancer.

How Alixorexton could transform narcolepsy treatment
A new investigational drug, alixorexton, targets the brain’s orexin system to restore wakefulness in people with narcolepsy type 1. Alkermes chemist Brian Raymer shares how molecular modeling turned a lab idea into a promising phase 3 therapy.